X4 Pharmaceuticals, Inc. cash flow to debt ratio of -110.78% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

X4 Pharmaceuticals, Inc.'s free cash flow has increased -35.89% from $-138.23M last year to $-88.62M, signaling increasing performance

X4 Pharmaceuticals, Inc.'s debt to equity ratio is 0.46, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

X4 Pharmaceuticals, Inc.'s debt has decreased relative to shareholder equity from 3.53 last year to 0.46 today, signaling strengthened financials

X4 Pharmaceuticals, Inc. has negative EBITDA, making leverage ratio unreliable

X4 Pharmaceuticals, Inc.'s interest coverage ratio is -11.10, which means that the company struggles to meet interest obligations, signaling financial risk.

X4 Pharmaceuticals, Inc.'s profit margin has increased (-24.46%) in the last year from -1.46K% to -1.11K%, signaling increasing performance

X4 Pharmaceuticals, Inc.'s short-term assets of $261.58M exceed its short-term liabilities of $25.76M

X4 Pharmaceuticals, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

X4 Pharmaceuticals, Inc.'s return on equity of -94.90%, is lower than 15.00%, indicating bad performance

X4 Pharmaceuticals, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

X4 Pharmaceuticals, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

X4 Pharmaceuticals, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

X4 Pharmaceuticals, Inc. has negative free cash flow, indicating cash burn

X4 Pharmaceuticals, Inc.'s yearly earnings has decreased 111.48% since last year from $-37.45M to $-79.20M, signaling decreasing performance

X4 Pharmaceuticals, Inc.'s yearly revenue has increased 1.27K% since last year from $2.56M to $35.11M, signaling increasing performance

ROIC -39.53% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

X4 Pharmaceuticals, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

X4 Pharmaceuticals, Inc. had revenue growth in 4.00 out of 5 years, indicating consistent revenue performance

X4 Pharmaceuticals, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

X4 Pharmaceuticals, Inc. has insufficient data to evaluate this check.

X4 Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

X4 Pharmaceuticals, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

X4 Pharmaceuticals, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

X4 Pharmaceuticals, Inc. is overvalued relative to its fair value price of -134.26 based on Earnings Fair Value model

X4 Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

X4 Pharmaceuticals, Inc. has a price-to-book ratio of 3.01x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

X4 Pharmaceuticals, Inc. has a price-to-sales ratio of 56.30x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue